Format

Send to

Choose Destination
Int J Food Sci Nutr. 2017 Feb;68(1):28-42. doi: 10.1080/09637486.2016.1216525. Epub 2016 Aug 9.

Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies.

Author information

1
a School of Public Health, Jiamusi University , Jiamusi , China.
2
b Department of Neurology , Zhongnan Hospital of Wuhan University , Wuhan , China.
3
c College of Life Science, Jiamusi University , Jiamusi , China.
4
d College of Basic Medicine, Jiamusi University , Jiamusi , China.
5
e Bio-Vaccine Limited Liability Company, Harbin Pharmaceutical Group , Harbin , China.

Abstract

This updated meta-analysis was performed to clarify the relationship between phytoestrogens and prostate cancer risk. Twenty one case-control and two cohort studies were finally selected for this meta-analysis, totaling 11,346 cases and 140,177 controls. Analytical results showed that daidzein (OR = 0.85; 95% CI: 0.75-0.96), genistein (OR = 0.87; 95% CI: 0.78-0.98), and glycitein (OR = 0.89; 95% CI: 0.81-0.98) were associated with a reduction of prostate cancer risk, but total isoflavones (OR = 0.93; 95% CI: 0.84-1.04), equol (OR = 0.86; 95% CI: 0.66-1.14), total lignans (OROgna.05; 95% CI: 0.54-2.04), secoisolariciresinol (OR = 1.02; 95% CI: 0.83-1.24), matairesinol (OR = 0.91; 95% CI: 0.75-1.11), enterolactone (OR = 0.94; 95% CI: 0.73-1.20), and coumestrol (OR = 0.89; 95% CI: 0.76-1.06) were not. Sensitivity and publication bias analyses demonstrated that the pooled estimates were stable and reliable. The results support the notion that some phytoestrogens may have a role in decreasing the risk of prostate cancer. Additional large and well-designed cohort studies are needed to confirm these relationships.

KEYWORDS:

Phytoestrogens; isoflavones; meta-analysis; prostate cancer; risk

PMID:
27687296
DOI:
10.1080/09637486.2016.1216525
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center